Difference between revisions of "Daratumumab (Darzalex)"
Warner-admin (talk | contribs) m (Text replacement - "[[Category:Drugs FDA" to "[[Category:FDA") |
m |
||
Line 7: | Line 7: | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
+ | *[[Light-chain (AL) amyloidosis]] | ||
*[[Multiple myeloma]] | *[[Multiple myeloma]] | ||
Line 26: | Line 27: | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
− | |||
[[Category:Intravenous medications]] | [[Category:Intravenous medications]] | ||
[[Category:Antibody medications]] | [[Category:Antibody medications]] | ||
[[Category:Anti-CD38 antibodies]] | [[Category:Anti-CD38 antibodies]] | ||
+ | |||
+ | [[Category:Light-chain (AL) amyloidosis medications]] | ||
[[Category:Multiple myeloma medications]] | [[Category:Multiple myeloma medications]] | ||
[[Category:FDA approved in 2015]] | [[Category:FDA approved in 2015]] |
Revision as of 02:09, 23 August 2018
General information
Class/mechanism: Anti-CD38 antibody, human monoclonal IgG1 kappa. Daratumumab binds to CD38 and causes apoptosis in CD38-expressing cells via Fc mediated cross-linking, complement-dependent cytotoxicity (CDC), antibody-dependent cell mediated cytotoxicity (ADCC), and antibody dependent cellular phagocytosis (ADCP). CD38 is present on the cell surface of multiple myeloma (MM), plasma leukemia, and natural killer (NK) cells.[1][2][3][4]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Daratumumab (Darzalex) package insert[1]
- Daratumumab (Darzalex) patient drug information (Chemocare)[5]
- Daratumumab (Darzalex) patient drug information (UpToDate)[6]
History of changes in FDA indication
- 11/16/2015: Granted FDA accelerated approval "for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent or who are double-refractory to a PI and an immunomodulatory agent."[1]
- 11/21/2016: FDA approved "in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy."
Also known as
- Code name: JNJ-54767414
- Brand names: Darzalex, HuMax-CD38
References
- ↑ 1.0 1.1 1.2 1.3 Daratumumab (Darzalex) package insert
- ↑ Daratumumab (Darzalex) package insert (locally hosted backup)
- ↑ Daratumumab page at NCI Drug Dictionary
- ↑ Darzalex manufacturer's website
- ↑ Daratumumab (Darzalex) patient drug information (Chemocare)
- ↑ Daratumumab (Darzalex) patient drug information (UpToDate)